Day One Biopharmaceuticals, Inc.
NASDAQ:DAWN
Overview | Financials
Company Name | Day One Biopharmaceuticals, Inc. |
Symbol | DAWN |
Currency | USD |
Price | 12.79 |
Market Cap | 1,289,820,340 |
Dividend Yield | 0% |
52-week-range | 11.94 - 18.07 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
Website | https://dayonebio.com |
An error occurred while fetching data.
About Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD